CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL

The chimeric antigen receptor (CAR) T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL), according to results from a phase I trial presented at the 2015 AACR Annual Meeting.

See more at: http://www.onclive.com/web-exclusives/CAR-T-Cell-Therapy-Surpasses-90-Complete-Remission-Rate-in-Pediatric-ALL#sthash.eXvTAuNM.dpuf